These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 26033281)

  • 1. Cost-Effectiveness of Autologous Hematopoietic Stem Cell Transplantation for Elderly Patients with Multiple Myeloma using the Surveillance, Epidemiology, and End Results-Medicare Database.
    Shah GL; Winn AN; Lin PJ; Klein A; Sprague KA; Smith HP; Buchsbaum R; Cohen JT; Miller KB; Comenzo R; Parsons SK
    Biol Blood Marrow Transplant; 2015 Oct; 21(10):1823-9. PubMed ID: 26033281
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Autologous haemopoietic stem-cell transplantation followed by allogeneic or autologous haemopoietic stem-cell transplantation in patients with multiple myeloma (BMT CTN 0102): a phase 3 biological assignment trial.
    Krishnan A; Pasquini MC; Logan B; Stadtmauer EA; Vesole DH; Alyea E; Antin JH; Comenzo R; Goodman S; Hari P; Laport G; Qazilbash MH; Rowley S; Sahebi F; Somlo G; Vogl DT; Weisdorf D; Ewell M; Wu J; Geller NL; Horowitz MM; Giralt S; Maloney DG;
    Lancet Oncol; 2011 Dec; 12(13):1195-203. PubMed ID: 21962393
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The real world effectiveness of hematopoietic transplant among elderly individuals with multiple myeloma.
    Winn AN; Shah GL; Cohen JT; Lin PJ; Parsons SK
    J Natl Cancer Inst; 2015 Aug; 107(8):. PubMed ID: 26023094
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multiple myeloma treatment transformed: a population-based study of changes in initial management approaches in the United States.
    Warren JL; Harlan LC; Stevens J; Little RF; Abel GA
    J Clin Oncol; 2013 Jun; 31(16):1984-9. PubMed ID: 23569317
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of the affordability of novel agents in patients with multiple myeloma: Real-world data of current clinical practice in Mexico.
    Tarín-Arzaga L; Arredondo-Campos D; Martínez-Pacheco V; Martínez-González O; Ramírez-López A; Gómez-De León A; Gutiérrez-Aguirre CH; Cantú-Rodríguez O; Jaime-Pérez JC; Gómez-Almaguer D
    Cancer; 2018 May; 124(9):1946-1953. PubMed ID: 29461639
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Autologous transplantation in multiple myeloma: a GITMO retrospective analysis on 290 patients. Gruppo Italiano Trapianti di Midollo Osseo.
    Majolino I; Vignetti M; Meloni G; Vegna ML; Scimè R; Tringali S; Amaddii G; Coser P; Tribalto M; Raimondi R; Bergonzi C; Sajeva MR; Sica S; Ferrando F; Messina G; Mandelli F
    Haematologica; 1999 Sep; 84(9):844-52. PubMed ID: 10477460
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Racial disparities in treatment patterns and outcomes among patients with multiple myeloma: a SEER-Medicare analysis.
    Ailawadhi S; Parikh K; Abouzaid S; Zhou Z; Tang W; Clancy Z; Cheung C; Zhou ZY; Xie J
    Blood Adv; 2019 Oct; 3(20):2986-2994. PubMed ID: 31648322
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness of a transplantation strategy compared to melphalan and prednisone in younger patients with multiple myeloma.
    Kouroukis CT; O'Brien BJ; Benger A; Marcellus D; Foley R; Garner J; Ingram C; Haines P; Henderson-O'Connor N; Meyer R
    Leuk Lymphoma; 2003 Jan; 44(1):29-37. PubMed ID: 12691140
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Outcome of autologous hematopoietic stem cell transplantation in refractory multiple myeloma.
    Veltri LW; Milton DR; Delgado R; Shah N; Patel K; Nieto Y; Kebriaei P; Popat UR; Parmar S; Oran B; Ciurea S; Hosing C; Lee HC; Manasanch E; Orlowski RZ; Shpall EJ; Champlin RE; Qazilbash MH; Bashir Q
    Cancer; 2017 Sep; 123(18):3568-3575. PubMed ID: 28513828
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Autologous haematopoietic stem-cell transplantation versus bortezomib-melphalan-prednisone, with or without bortezomib-lenalidomide-dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study.
    Cavo M; Gay F; Beksac M; Pantani L; Petrucci MT; Dimopoulos MA; Dozza L; van der Holt B; Zweegman S; Oliva S; van der Velden VHJ; Zamagni E; Palumbo GA; Patriarca F; Montefusco V; Galli M; Maisnar V; Gamberi B; Hansson M; Belotti A; Pour L; Ypma P; Grasso M; Croockewit A; Ballanti S; Offidani M; Vincelli ID; Zambello R; Liberati AM; Andersen NF; Broijl A; Troia R; Pascarella A; Benevolo G; Levin MD; Bos G; Ludwig H; Aquino S; Morelli AM; Wu KL; Boersma R; Hajek R; Durian M; von dem Borne PA; Caravita di Toritto T; Zander T; Driessen C; Specchia G; Waage A; Gimsing P; Mellqvist UH; van Marwijk Kooy M; Minnema M; Mandigers C; Cafro AM; Palmas A; Carvalho S; Spencer A; Boccadoro M; Sonneveld P
    Lancet Haematol; 2020 Jun; 7(6):e456-e468. PubMed ID: 32359506
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-Effectiveness of Novel Agents in Medicare Patients with Multiple Myeloma: Findings from a U.S. Payer's Perspective.
    Chen Y; Lairson DR; Chan W; Huo J; Du XL
    J Manag Care Spec Pharm; 2017 Aug; 23(8):831-843. PubMed ID: 28737990
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative survival, quality of life and cost-effectiveness of intensive therapy with autologous blood cell transplantation or conventional chemotherapy in multiple myeloma.
    Henon P; Donatini B; Eisenmann JC; Becker M; Beck-Wirth G
    Bone Marrow Transplant; 1995 Jul; 16(1):19-25. PubMed ID: 7581122
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Survival of multiple myeloma patients aged 65-70 years in the era of novel agents and autologous stem cell transplantation. A multicenter retrospective collaborative study of the Japanese Society of Myeloma and the European Myeloma Network.
    Ozaki S; Harada T; Saitoh T; Shimazaki C; Itagaki M; Asaoku H; Kuroda Y; Chou T; Yoshiki Y; Suzuki K; Murakami H; Hayashi K; Mina R; Palumbo A; Shimizu K; ;
    Acta Haematol; 2014; 132(2):211-9. PubMed ID: 24662986
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of the feasibility and efficacy of autologous stem cell transplantation in elderly patients with multiple myeloma.
    Muta T; Miyamoto T; Fujisaki T; Ohno Y; Kamimura T; Kato K; Takenaka K; Iwasaki H; Eto T; Takamatsu Y; Teshima T; Akashi K;
    Intern Med; 2013; 52(1):63-70. PubMed ID: 23291675
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Multiple myeloma: Maintenance therapy after autologous hematopoietic stem cell transplantation, depending on minimal residual disease].
    Solovyev MV; Mendeleeva LP; Pokrovskaya OS; Nareyko MV; Firsova MV; Galtseva IV; Davydova YO; Kapranov NM; Kuzmina LA; Gemdzhian EG; Savchenko VG
    Ter Arkh; 2017; 89(7):25-31. PubMed ID: 28766537
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of chemotherapy on the mobilisation, harvest and economic costs of autologous peripheral stem cell transplantation in patients with multiple myeloma.
    Jerjis S; Croockewit S; Preijers F; Schaap N; De Witte T
    Leuk Lymphoma; 2000 May; 37(5-6):551-60. PubMed ID: 11042515
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Autologous stem cell transplantation in first remission is associated with better progression-free survival in multiple myeloma.
    Aggarwal M; Agrawal N; Yadav N; Verma P; Ahmed R; Mehta P; Kapoor J; Bhurani D
    Ann Hematol; 2018 Oct; 97(10):1869-1877. PubMed ID: 29781040
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness of carfilzomib plus dexamethasone compared with bortezomib plus dexamethasone for patients with relapsed or refractory multiple myeloma in the United States.
    Jakubowiak AJ; Houisse I; Májer I; Benedict Á; Campioni M; Panjabi S; Ailawadhi S
    Expert Rev Hematol; 2017 Dec; 10(12):1107-1119. PubMed ID: 29027825
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pegfilgrastim improves the outcomes of mobilization and engraftment in autologous hematopoietic stem cell transplantation for the treatment of multiple myeloma.
    Ding X; Huang W; Peng Y; Fan H; Zhu Y; Liu X; Yang Y; Guo Q; Qiu L; Dai Y; Zou D; Jin F
    Ann Hematol; 2020 Jun; 99(6):1331-1339. PubMed ID: 32382775
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Temporal trends in treatment and survival of older adult diffuse large B-Cell lymphoma patients in the SEER-Medicare linked database.
    Shaw J; Harvey C; Richards C; Kim C
    Leuk Lymphoma; 2019 Dec; 60(13):3235-3243. PubMed ID: 31185769
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.